Wednesday, January 08, 2014 8:33:31 AM
Nice buy!
Email: sheepery@gmail.com
Recent CPRX News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/12/2026 01:05:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 08:33:41 PM
- Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/11/2026 08:12:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 08:10:11 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/08/2026 09:20:29 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/07/2026 09:27:54 PM
- Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast • GlobeNewswire Inc. • 05/07/2026 08:02:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/07/2026 01:00:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:45:27 PM
- Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease • GlobeNewswire Inc. • 05/07/2026 07:25:34 AM
- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd. • GlobeNewswire Inc. • 05/07/2026 06:44:12 AM
- Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease • GlobeNewswire Inc. • 05/07/2026 06:14:01 AM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/30/2026 08:30:58 PM
- Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026 • GlobeNewswire Inc. • 04/28/2026 12:03:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 09:23:18 PM
- Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance • GlobeNewswire Inc. • 02/25/2026 09:07:55 PM
- Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference • GlobeNewswire Inc. • 02/24/2026 01:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 10:04:15 PM
- Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:03:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 01:03:17 PM
- Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies • GlobeNewswire Inc. • 01/08/2026 01:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:30 PM
- The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) • GlobeNewswire Inc. • 01/05/2026 01:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/30/2025 10:00:26 PM
